Valeant Pharmaceuticals International (VRX)

mrbill6 (< 20) Submitted: 10/29/2009 8:16:43 PM : Start Price: $29.38 VRX Score: +7.92

moneycentral rated: 10, navallier rated:A

ronaldglatts (86.06) Submitted: 6/23/2009 6:28:52 PM : Start Price: $24.10 VRX Score: +13.26

Insider trading

Beebzer (85.63) Submitted: 5/20/2009 1:34:09 AM : Start Price: $22.92 VRX Score: +22.06

Building a portfolio based on insider cluster buys.

zzlangerhans (99.52) Submitted: 5/14/2008 11:39:01 PM : Start Price: $15.73 VRX Score: -128.68

Both RESTORE trials showed favorable results, and the stock price has risen correspondingly. However, the eventual revenue prospects for retigabine in the crowded anti-epipleptic market are dubious. The company is downplaying taribavirin and appears to be trying to dish it off to some sucker, I mean partner. As far as revenues from marketed products, I can't improve on the CEO's own comments. "The financial results from this quarter continue to highlight the need for decisive change at Valeant," Chief Executive Officer J. Michael Pearson said in a statement. Translation - we suck. The top commerical priority of the company is to improve their marketing in Mexico. Ahem. Hopefully this pick will bring me back to my rightful position as score leader.

crimfunk (76.30) Submitted: 2/2/2008 1:21:34 AM : Start Price: $11.00 VRX Score: +217.62

undervalued, EPS 5 Year Growth (%) 199.82

hennessy7 (< 20) Submitted: 10/10/2007 11:27:13 AM : Start Price: $15.56 VRX Score: +138.01

I was long on this stock until my stop loss triggered. Looks like it may trend down before coming back up. Not willing to bet my $ but I will put it on CAPS.